drugset / Trial / NCT02635061
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
Timeline
- Start
- 2016-08-25
- Primary completion
- 2024-01-22
- Completion
- 2024-01-22
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citarinostat | Small molecule | 180 mg | Oral |
| Subject | Citarinostat | Small molecule | 360 mg | Oral |
| Subject | Citarinostat | Small molecule | 480 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |